The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, X4 Pharmaceuticals Inc’s stock clocked out at $0.62, down -1.35% from its previous closing price of $0.63. In other words, the price has decreased by -$1.35 from its previous closing price. On the day, 0.94 million shares were traded. XFOR stock price reached its highest trading level at $0.65 during the session, while it also had its lowest trading level at $0.6177.
Ratios:
To gain a deeper understanding of XFOR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.04 and its Current Ratio is at 6.07. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.82.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 12, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $3 previously.
On December 22, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on December 22, 2022, with a $3 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 09 ’24 when DiBiase Mary sold 2,642 shares for $0.66 per share. The transaction valued at 1,738 led to the insider holds 289,110 shares of the business.
DiBiase Mary bought 2,642 shares of XFOR for $1,728 on Sep 09 ’24. On Mar 11 ’24, another insider, Taveras Arthur, who serves as the Chief Scientific Officer of the company, sold 14,235 shares for $0.88 each. As a result, the insider received 12,552 and left with 234,301 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XFOR now has a Market Capitalization of 104672208 and an Enterprise Value of 14145898. As of this moment, X4’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.26. For the stock, the TTM Price-to-Sale (P/S) ratio is 186.91 while its Price-to-Book (P/B) ratio in mrq is 1.11. Its current Enterprise Value per Revenue stands at 25.126 whereas that against EBITDA is -0.115.
Stock Price History:
Over the past 52 weeks, XFOR has reached a high of $1.60, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is -10.72%, while the 200-Day Moving Average is calculated to be -30.46%.
Shares Statistics:
It appears that XFOR traded 1.22M shares on average per day over the past three months and 700410 shares per day over the past ten days. A total of 167.43M shares are outstanding, with a floating share count of 117.80M. Insiders hold about 30.09% of the company’s shares, while institutions hold 38.60% stake in the company. Shares short for XFOR as of 1726185600 were 13621228 with a Short Ratio of 11.15, compared to 1723680000 on 15374627. Therefore, it implies a Short% of Shares Outstanding of 13621228 and a Short% of Float of 8.1599995.
